æ°åã³ããã»ã¯ã¯ãã³ã®å ¬çæ©é¢æ å ±ãŸãšã
ããããã«ããµããã³ããã»ã¯ã¯ãã³ã®æ
å ±ã§ããããã®ã»ãšãã©ã¯åºæã®åãããªãç»åãåç»ã§ãã
ããããã玹ä»ããæ
å ±ã¯å
šãŠãåœå
å€ã®å
¬çæ©é¢ãååŽçãåœå
å€ã®ãã¥ãŒã¹ãªã©ãåŒçšããã¿ãªããããèªèº«ã§ç¢ºèªã§ããããåŒçšãªã³ã¯ãæèšããŠããŸãã
1ïŒåºç€ç·š
ãæ¥æ¬ã«ãŠç¬¬äžåæ¥çš®ãæ¬æ Œåããã®ã¯2021幎å€ããã§ãããããã®åºæ¬çãªæ å ±ãã¡ãã£ã¢ãæ¿åºããååã«ééããã£ããã©ãããæãåºããŠããããªããèªãã§ããã ãããã§ãã
1-1ïŒæ°åã³ããã¯ã¯ãã³ã¯æªæ¿èªãªã®ã
ã¢ã¡ãªã«ã«ãŠ2021幎8æ23æ¥ãŸã§
ããã¡ã€ã¶ãŒïŒæªæ¿èªïŒç·æ¥äœ¿çšèš±å¯ïŒEUAïŒïŒ
ãã¢ãã«ããïŒæªæ¿èªïŒç·æ¥äœ¿çšèš±å¯ïŒEUAïŒïŒ
ãã€ã³ã
ãç·æ¥äœ¿çšèš±å¯ãšéåžžã®æ¿èªã®éãã説æãããŸãããã
2021幎8æ23æ¥ä»¥é
ããã¡ã€ã¶ãŒïŒ16æ³ä»¥äžã§æ£åŒæ¿èªã15æ³ä»¥äžã¯ç·æ¥äœ¿çšã®ãŸãŸã
ãã¢ãã«ããïŒç·æ¥äœ¿çšã®ãŸãŸã
ãœãŒã¹ãªã³ã¯
ãNHKïŒã¢ã¡ãªã«FDA ãã¡ã€ã¶ãŒã®ã¯ã¯ãã³ãæ£åŒã«æ¿èª
ãFDAïŒãã¡ã€ã¶ãŒïŒïŒã¯ã¯ãã³æ¥çš®ãåãã人ãšä»è·åŸäºè
ã®ããã®ãã¡ã¯ãã·ãŒã (fda.gov)
ãFDAïŒã¢ãã«ãïŒïŒã¯ã¯ãã³æ¥çš®ãåãã人ãšä»è·åŸäºè
ã®ããã®ãã¡ã¯ãã·ãŒã (fda.gov)
æ¥æ¬ã«ãŠ
ããã¡ã€ã¶ãŒïŒ2021幎2æ14æ¥ã«ç¹äŸæ¿èª
ãã¢ãã«ããïŒ2021幎5æ21æ¥ã«ç¹äŸæ¿èªïŒæŠç°è¬åå·¥æ¥æ ªåŒäŒç€ŸïŒ
ãã€ã³ã
ãç¹äŸæ¿èªãšéåžžã®æ¿èªã®éãã説æãããŸãããã
ãœãŒã¹ãªã³ã¯
ãååŽçïŒæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®ç¹äŸæ¿èªã«ã€ããŠïŒ2021幎2æ14æ¥ïŒ
ãããããæ°åã³ãããŠã€ã«ã¹ã¯ã¯ãã³ã®ç¹äŸæ¿èªã«ã€ããŠïŒ2021幎5æ21æ¥ïŒ
æ³šïŒææ°æ å ±ã远ããŠããªãå¯èœæ§ããããŸãã
1-2ïŒæ°åã³ããã¯ã¯ãã³ã¯æ²»éšäžãªã®ã
æ²»éšâèšåºè©ŠéšïŒç¬¬â
¢çžè©ŠéšïŒã¯çµãã£ãŠãããããã
ãœãŒã¹ãªã³ã¯
ãååŽçïŒæ°åã³ããã¯ã¯ãã³ã®èšåºè©ŠéšïŒæ²»éšïŒãçµãã£ãŠããªããšããã®ã¯æ¬åœã§ãã
ååŽçããŒãžããæç²
ãç±³åœFDAã®ã¬ã€ãã³ã¹ã§ã¯ïŒäžç¥ïŒç·æ¥äœ¿çšãèš±å¯ããããã«ãæ¥çš®åŸèг坿éã®äžå€®å€ã2ã¶æéããããšãäžã€ã®èŠä»¶ãšããŸããã
ïŒäžç¥ïŒæ¥æ¬åœå
ã§ããæ¥æ¬äººã察象ã«èšåºè©ŠéšïŒç¬¬â
/â
¡çžè©ŠéšïŒã宿œãã
ïŒäžç¥ïŒäžéšã®èšåºè©Šéšã®çµäºäºå®ææããå°æ¥ã®æ¥ä»ã«ãªã£ãŠããå ŽåããããŸããïŒäžç¥ïŒããé·æã«æå¹æ§ãå®å
šæ§ãèªãããããã©ããã«ã€ããŠãåŒãç¶ãæ
å ±åéãè¡ãããŠããããã§ãã
ãã€ã³ã
ãç·æ¥äœ¿çšã®ãããèŠ³å¯æéã2ã«æã§ããããšã説æãããŸãããã
ãäžéšã®èšåºè©Šéšã®çµäºäºå®ææããå°æ¥ã®æ¥ä»ã«ãªã£ãŠããããšã説æãããŸãããã
ãé·æã«æå¹æ§ãå®å
šæ§ãèªãããããã©ããã«ã€ããŠãåŒãç¶ãæ
å ±åéãè¡ãããŠãããé説çã«é·æã®æå¹æ§ãå®å
šæ§ãå¿
ãããèªããããŠããªãããšã説æãããŸãããã
ããŸããååŽçããŒãžã®ã¢ã³ãµãŒã§ã¯ç¬¬â
¢çžè©Šéšãçµãã£ãããã«æžããŠãããŸãããæ¬æã§ã¯èšåããªãããšã¯å人çã«æ°ã«ãªããŸãã
è£è¶³1
ãååŽçã®è³æã«ãŠç¬¬â
çžè©Šéšã®è©ŠéšæéãçŽ0.5ïœ1幎ã第â
¡çžè©ŠéšåæãçŽ1幎ã第â
¡çžè©ŠéšåŸæãçŽ1幎ã第â
¢çžè©ŠéšãçŽ2ïœ3幎ïŒèšçŽ4.5ïœ6幎ïŒãšããåºæºãé å®ãã¹ããšããŠèšããŠããŸãã
ãœãŒã¹ãªã³ã¯
ãååŽçïŒæ²»éšã«ã€ããŠïŒ2ããŒãžç®ïŒ
ãæ¥ãããã§ã¯ã¯ãã³ãéçºãããšããäºæ
ãããã§ããããã2ã«æã®èг坿éã§å®å
šã ãšèšãåãã®ã¯æ¬åœã«æ£ããã®ã§ããããã
è£è¶³2
ã補é 販売åŸèšåºè©ŠéšïŒç¬¬â
£çžè©ŠéšïŒã¯æªãïŒè±èªã§ã¯ç¬¬â
¢çžè©Šéšã»ç¬¬â
£çžè©Šéšãšãã« Clinical TrialsïŒ
ããã¡ã€ã¶ãŒã® Clinical Trials ã®å®äºã¯2024幎2æ8æ¥
ãã¢ãã«ãã® Clinical Trials ã®å®äºã¯2022幎10æ27æ¥
ãœãŒã¹ãªã³ã¯ïŒãªã³ã¯ã®Study DesignãEstimatedãåç
§ïŒ
ãClinicalTrials.govïŒãã¡ã€ã¶ãŒ
ãããããããããã¢ãã«ã
ïŒClinicalTrials.govã¯ã¢ã¡ãªã«åœç«è¡çç ç©¶æã®åœç«å»åŠå³æžé€šã«ãã£ãŠäœãããäžçæå€§ã®èšåºè©Šéšç»é²ãµã€ãïŒ
1-3ïŒéºäŒåã¯ã¯ãã³ãšã¯
ãããªãã®çްèããã¹ãã€ã¯ã¿ã³ãã¯ã®çç£å·¥å Žãã«ããŸãã
ãœãŒã¹ãªã³ã¯
ãNHKïŒmRNAã¯ã¯ãã³ãšã¯ïŒ
NHKããæç²
ããã¡ã€ã¶ãŒãªã©ã®ã¯ã¯ãã³ãã¢ãã«ãã®ã¯ã¯ãã³ã¯ããããããmRNAããšããç©è³ªã䜿ã£ããmRNAã¯ã¯ãã³ãã§ãã
ãmRNAã¯ã¯ãã³ã¯ããŠã€ã«ã¹ã®è¡šé¢ã«ãããã¹ãã€ã¯ããã±ã質ããšåŒã°ããããã±ã質ã®éºäŒæ
å ±ãå«ãã ãmRNAããããã®äœå
ã«æäžããŸãã
ããã®ãmRNAãã¯ããã®çްèã®äžã§èšèšå³ã®ããã«åããŠæ¬¡ã
ãšã¹ãã€ã¯ããã±ã質ãäœãããŸãã
è£è¶³
ãåŸæ¥ã®ã¯ã¯ãã³ã¯ã匱æ¯åãããŠã€ã«ã¹ã泚å
¥ããçã¯ã¯ãã³ããæ¯æ§ããªããããŠã€ã«ã¹ã泚å
¥ããäžæŽ»åã¯ã¯ãã³ãã§ãã
ãœãŒã¹ãªã³ã¯
ãNHKïŒã¯ã¯ãã³ã®çš®é¡
ãã€ã³ã
ãåŸæ¥ã®ã¯ã¯ãã³ãã匱ããããŠã€ã«ã¹ããæ¯æ§ããªããããŠã€ã«ã¹ãäœå
ã«å
¥ãããã®ã ãšèª¬æãããŸãããã
ãéºäŒæ
å ±ãå«ãã mRNAãäœå
ã«å
¥ããããã®çްèã®äžã§èšèšå³ã®ããã«åããŠæ¬¡ã
ãšã¹ãã€ã¯ããã±ã質ãäœã£ãŠããããšã説æãããŸãããã
1-4ïŒã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ã»å¯åå¿å ±å
ãååŽçã®åçç§åŠå¯©è°äŒïŒå¯åå¿æ€èšéšäŒïŒã«å ±åãããå¯åå¿çãã¯å»çæ©é¢ããå ±åããããã®ãšã補é 販売æ¥è ããå ±åããããã®ã«åãããŠããŸãã
ãœãŒã¹ãªã³ã¯
第78ååçç§åŠå¯©è°äŒïŒå¯åå¿æ€èšéšäŒã2022幎4æ13æ¥ïŒ
ãå»çæ©é¢ããã®å¯åå¿å ±åçãïŒè³æïŒïŒïŒïŒïŒã®ïŒããŒãžïŒ
ããæ»äº¡å ±åïŒ1,259ä»¶
ããéç¯€å ±åïŒ6,933ä»¶
ããå¯åå¿çãå ±åïŒ32,694ä»¶
ã補é 販売æ¥è
ããã®å¯åå¿å ±åçãïŒè³æïŒïŒïŒïŒïŒã®ïŒããŒãžïŒ
ããæ»äº¡å ±åïŒ1,550ä»¶
ããå¯åå¿çãå ±åïŒé節ïŒïŒ21,131ä»¶
泚ïŒäž¡å ±åã¯éè€ãå«ã¿ãŸãã
ãã€ã³ã
ãæ¥æ¬ã®ã¯ã¯ãã³æ¥çš®ã¯æ¬§ç±³ã«æ¯ã¹ãŠé
ããŠãããããæ¥æ¬ã§ã®æ¥çš®æç¹ã§æµ·å€ã§ã¯å€ãã®æ»äº¡å ±åã»éç¯€å ±åãäžãã£ãŠããŸããããã®èª¬æã¯ãããŸãããã
ã¢ã¡ãªã«ã§ã¯VAERSïŒæå®³äºè±¡å ±åæžïŒã«å ±åããŸãšããããŠããŸããïŒ2022幎4æ22æ¥ïŒ
ãDeathsïŒæ»äº¡ïŒïŒ27,532ä»¶
ãHOSPITALIZATIONSïŒå
¥é¢ïŒïŒ152,946ä»¶
ãURGENT CAREïŒç·æ¥æªçœ®ïŒïŒ128,134ä»¶
ãDOCTOR OFFICE VISITSïŒç
é¢èšªåïŒïŒ189,907ä»¶
ãANAPHYLAXISïŒã¢ããã£ã©ãã·ãŒïŒïŒ9,643ä»¶
ãBELL'S PALSYïŒãã«éº»çºïŒïŒ15,327ä»¶
ãMiscarriagesïŒæµç£ïŒïŒ4,570ä»¶
ãHeart AttacksïŒå¿èçºäœïŒïŒ14,096ä»¶
ãMyocarditis / PericarditisïŒå¿çç/å¿èçïŒïŒ39,639ä»¶
ãPermanently DisabledïŒå埩äžèœã®é害ïŒïŒ51,163ä»¶
ãThrombocytopenia / Low PlateletïŒè¡å°æ¿æžå°ç / äœè¡å°æ¿ïŒïŒ6,494ä»¶
ãLife ThreateningïŒåœã®å±æ©ïŒïŒ30,748ä»¶
ãSevere Allergic ReactionïŒé床ã®ã¢ã¬ã«ã®ãŒïŒïŒ41,595ä»¶
ãShinglesïŒåž¯ç¶ç±ç¹ïŒïŒ13,599ä»¶
ãVAERSãšã¯ãç±³åœçŸç äºé²ç®¡çã»ã³ã¿ãŒïŒCDCïŒãšç±³åœé£åå»è¬åå±ïŒFDAïŒã«ãã£ãŠå ±å管çãããŠããã¯ã¯ãã³æå®³äºè±¡å ±åã·ã¹ãã ã®ããšã
2ïŒèå¯ç·š
2-1ïŒå ±åæŒãã®å¯èœæ§ãè³æãå ã«èå¯
ãåçç§åŠå¯©è°äŒã®æ»äº¡å ±åã1,550ä»¶ã ãšããŠãããã§å šãŠã®æ»äº¡ãé節åå¿ã®å±¥æŽãç¶²çŸ ããããšã¯åºæ¥ãŸããã
ãååŽçã®ãå»è¬åçè¡æ¿è©äŸ¡ã»ç£èŠå§å¡äŒå§å¡ããšããäŒè°ã®2ïŒ08ããããã第äžè å§å¡ã®äœè€å£éæ°ããå®éã®ã¯ã¯ãã³è¢«å®³è æ°ã¯10åãããé«ãå¯èœæ§ãããããšããè¶£æšã®çºèšãããããååŽçã¯ããã容èªããã®ã§ããïŒããšè©°ãå¯ã£ãŠããŸããïŒãã®åŸååŽçã¯ãã©ããã©ãã®çåŒã§ãïŒ
ãã¢ã¡ãªã«ã«ãããŠãVAERSã«å ±åãããæå®³äºè±¡ãšãå®éã®è¢«å®³è
æ°ã®ã®ã£ããã¯æ¹å€ãããŠããŸãã
ã2010幎ã®ç±³åœä¿å¥ç€ŸäŒçŠç¥çãžã®å ±åæžã§ã¯ãVAERSã«å ±åãããæå®³äºè±¡ã¯ãå
šäœã®1ããŒã»ã³ãæªæºããšãããŠããŸãã
ãœãŒã¹ãªã³ã¯
Electronic Support for Public Health - Vaccine Adverse Event Reporting System (ESP:VAERS)
æç²ïŒïŒäžç¥ïŒless than one percent reported to the Food and Drug Administration (FDA).
ãååŽçãFDAã¯10åã®1ïœ100åã®1æªæºã®å ±åããéããããŠããªããããããªãããšæããããããããååŽçãFDAãæ±ºããŠééããªãã絶察ã«å šãŠã®æ»äº¡ãšé節åå¿ã®å ±åãç¶²çŸ ããŠããã«éããªãããšæããããèªèº«ã§å€æäžããã
è£è¶³
ãæ¥æ¬ã«ãããŠãæ»äº¡äŸã®å ±åã¯å»åž«ã®å€æã«å§ããããŠããŸãã
ã第55ååçç§åŠå¯©è°äŒïŒäžç¥ïŒè°äºé²
æç²
â山瞣å§å¡ããã®æ»äº¡äŸã«é¢ããŠã®å ±åã«ã€ããŠã¯ãå»åž«ã®å€æã§å ±åãããã©ãããšããããšã決ããããŠãããšããçè§£ã§ããããã§ããããã
âäºåå±ã埡ææã®ãšãããå ±åãããã©ãããšããã®ã¯å»åž«ã®å
çã®åŸ¡å€æã§ããããŸããŠãå ±åãããããªçãããããã©ãããšãããµãã«å€æããã ããŠãããšæããŸãã
è£è¶³
ãå»åž«ã®å€æã§ãã¯ã¯ãã³æ¥çš®åŸãç¿æ¥ã®æ»äº¡ã§ãã£ãŠãåœãžã®å ±åãèŠéãã±ãŒã¹ãååšããŸãã
ãæ¥çš®ç¿æ¥ã«æ»äº¡ããç·æ§ã«ã€ããŠãå æé¢ä¿ã¯ãªããšã¿ãŠãã£ããåœãžã®å ±åãèŠéã£ãåŸãéºæã®æåãåããŠïŒæã«æ¥ãããå ±åããã±ãŒã¹ããããŸãã
ãœãŒã¹ãªã³ã¯
ãèªå£²æ°èïŒæ¥çš®åŸã«æ»äº¡ãå ±åæ©ãå»çæ©é¢âŠéºæã¯ãåœã«äŒããŠã
ããã®ãããªå人ã®äºäŸãäžã€äžã€è¿œããããããšã¯é£ããã§ãããTwitteräžã§ã®è¢«å®³è
ã®å£°ãçã®å£°ããŸãšããŠãããµã€ãããããŸãã1次æ
å ±ã§ã¯ãããŸããããèå³ãããæ¹ã¯åèäžããã
ãå ±åã¯æ°·å±±ã®äžè§ïŒã³ããã¯ã¯ãã³æ¥çš®åŸã®æ¬éãå¯åå¿ãæ»äº¡ã®ãã€ãŒããå€ãããŠæŠæ
ïŒâ
ãå ±åã¯æ°·å±±ã®äžè§ïŒã³ããã¯ã¯ãã³æ¥çš®åŸã®å¯åå¿ãæ»äº¡ã®ãã€ãŒããå€ãããŠæŠæ
ïŒvol.265
2-2ïŒäººå£åæ çµ±èšã®ç¢ºèª
ã人å£åæ çµ±èšã確èªããã°ãå»å¹Žãšä»å¹Žã®æ»äº¡è ã®éãã確èªã§ããŸãã
ããŸããæ±æ¥æ¬å€§éçœãèµ·ãã£ã2011幎ã®ããŒã¿ãããæ»äº¡æ°ã®åå¹Žåææ¯èŒãèŠãŠã¿ãŸãããã
ãååŽçïŒäººå£åæ
çµ±èš æå ±ïŒæŠæ°ïŒ2011幎12æ

ã倧éçœã®èµ·ãã£ã3æã«åå¹Žåææ¯ã®æ»äº¡æ°ã8,822人å¢å ã2010å¹Žã«æ¯ã¹ããšäžå¹ŽãéããŠæ»äº¡æ°ã56,397人å¢å ããŠããŸãã
ãæ¬¡ã«ã³ãããèµ·ããåã®2019幎ãšãã³ãããèµ·ãã£ã2020å¹Žã®æ¯èŒãããŸããã³ãããéšããå§ãããã®ã®ã¯ã¯ãã³ã®æ¥çš®ãç¡ãã£ã幎ã§ãã
ãååŽçïŒäººå£åæ
çµ±èš æå ±ïŒæŠæ°ïŒ2020幎12æ

ãæ¥æ¬ã§æåã«ã³ããéœæ§è
ãåºãã®ã2020幎1æ15æ¥ã§ããããããçŽäžå¹Žéã飿¥TVã§ã³ããã®è
åšãå ±éããŸããã
ã2019å¹Žã«æ¯ã¹ããšäžå¹ŽãéããŠæ»äº¡æ°ã8,450人æžå°ããŠããŸãã
ãæãããæ°åã³ãããŠã€ã«ã¹ãæµè¡ãããšã¯ã«ããã«ä¿¡ããããŸããã
ãæ¬¡ã«ã³ãããèµ·ãã£ãã®2020幎ãšãã¯ã¯ãã³ã®æ¥çš®ãéå§ãã2021å¹Žã®æ¯èŒãããŸããã¯ã¯ãã³æ¥çš®ãæ¬æ Œåããã®ã¯å€ããã§ããã
ãååŽçïŒäººå£åæ
çµ±èš æå ±ïŒæŠæ°ïŒ2021幎11æïŒ12æã®æŠæ°çºè¡šã¯æªã®ãã11æããŒã¿ã䜿çšïŒ

ã5æã«åå¹Žåææ¯ã®æ»äº¡æ°ã10,072人å¢å ã2020å¹Žã«æ¯ã¹ããš11ã«æãéããŠæ»äº¡æ°ã66,229人å¢å ããŠããŸãã倧éçœä»¥äžã«æ»äº¡è ãå¢å ããŠããŸãã
ãæåŸã«2022幎3æã®éå ±å€ã確èªããŸãããã
ãååŽçïŒäººå£åæ
çµ±èš æå ±ïŒéå ±å€ïŒ2022幎3æ

ã2æã«åå¹Žåææ¯ã®æ»äº¡æ°ã19,490人å¢å ã3æã«åå¹Žåææ¯ã®æ»äº¡æ°ã15,992人å¢å ããŠããŸãã
èå¯
ãããã¯ãããŸã§ç§å人ã®èå¯ã»æšè«ã§ã蚌æ ã¯ãããŸããã
ãç§ã¯ãååŽçãFDAã¯10åã®1ïœ100åã®1æªæºã®å ±åããéããããŠããªãããšèããŠããŸãã
ãååŽççºè¡šã®æ»äº¡å ±åæ°ã¯2022幎4æã§1,550ä»¶ã§ããã2021幎1æïœ2022幎3æãŸã§ã®äººå£åæ
çµ±èšãæ¯èŒãããš106,375人ãäŸå¹Žãããå€ãæ»äº¡ããŠããŸãã
ã106,375人ã1,550ä»¶ã§å²ããšçŽ67åãªã®ã§ãæ¥æ¬ã§å®éã«ã¯ã¯ãã³ãæ¥çš®ããŠæ»äº¡ããç·æ°ã10äžäººååŸãã£ãŠãäžæè°ã§ã¯ãªããšèããŠããŸãã
äºå®ãŸãšã
ãååŽçã«ã¯ã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ã1,550ä»¶å ±åãããŠããã2äžïœ3äžåŒ·ã®å¯åå¿çãå ±åããããŸããïŒ2022幎4æ13æ¥ïŒ
ãç±³VAERSã«ã¯ã¯ã¯ãã³æ¥çš®åŸã®æ»äº¡ã27,532ä»¶å ±åãããŠããã60äžïœ70äžã®å¯åå¿çãå ±åããããŸããïŒ2022幎4æ22æ¥ïŒ
ãæ¥æ¬ã®ç¬¬äžè
å§å¡ããã¢ã¡ãªã«ã®ä¿å¥ç€ŸäŒçŠç¥çãžã®å ±åæžã§ã¯ã10åã®1ïœ100åã®1æªæºã®å ±åããéããããŠããªãå¯èœæ§ããææããŠããŸãã
ãæ¥æ¬ã§ã¯2020幎ïœ2022幎3æãŸã§ã®äººå£åæ
çµ±èšãæ¯èŒãããš106,375人ãäŸå¹Žãããå€ãæ»äº¡ããŠããããããã¯ã¯ãã³ãåå ã ãšèããã®ã¯æšå®ã§ããã15ã«æã§10äžäººå€ãæ»äº¡ããŠããããšã¯äºå®ã§ãã
2-3ïŒæ¿åºã¯äœåºŠã¯ã¯ãã³ãæã€ã€ãããªã®ã
ã2021/8/27ã®æç¹ã§æ¿åºã¯6å8400äžååã®ã¯ã¯ãã³ç¢ºä¿ã補è¬äŒç€Ÿãšåè°ããŠããŸãã
ãœãŒã¹ãªã³ã¯
ãYahooãã¥ãŒã¹ïŒã¯ã¯ãã³äŸ¡æ Œã1å2400åãæ¿åºã確ä¿ã«1.6å
å
ãæ¥æ¬ã®å
šäººå£ãæ¥çš®ãããšããŠã5åä»¥äžæã€èšç®ã«ãªããŸããæåããã2åã®æ¥çš®ã§æžããšèããŠãããšã¯æããŸããã
ãåœæã®å ±éã¯ã©ãã§ãããã2åæãŠã°ãã倧äžå€«ãšããå ±éãå€ãã£ãã®ã§ã¯ãªãã§ããããã
ã2åæ¥çš®ãŸã§ã¯æ¥çš®ççŽ8å²ã§ããããæ¥çš®çã¯æ®µã
ãšèœã¡ãŠããã§ããããæã¡ç¶ãã人ã¯10åãããæã€ããšã«ãªãããã§ãã
2-4ïŒæ°åã³ãããŠã€ã«ã¹ã®çµ±èš
ããããŸã§ã¯ã¯ãã³ã®çæäºé ãšæ»äº¡å ±åæ°ã®èå¯ãè¡ã£ãŠããŸããããããããæ°åã³ãããŠã€ã«ã¹ã®å±éºæ§ãååŽçã®çµ±èšããèå¯ããŠãããŸãã
ååŽçïŒæ°åã³ãããŠã€ã«ã¹ææçã®åœå
çºçååïŒéå ±å€ïŒ2021幎3æ3æ¥
ãå
ã«èå¯ããŸãã
ãæ¥æ¬ã§æåã«ã³ããéœæ§è ãåºãã®ã2020幎1æ15æ¥ã§ãããããã13ã«æåçµéããã2021幎3æ3æ¥ãŸã§ã«ã³ããã«é¢é£ããæ»äº¡è æ°ã¯7,366人ã§ãã

ã10代以äžã®æ»è
ã¯0人ã
ã20ä»£ã®æ»è
ã¯3人ã30代ã¯16人ã§ãããéœæ§è
æ°ã¯20代ã94,472人ã30代ã64,755人ã§ããå°æ°ç¹ãå°ããããŠæ»äº¡çã¯30å°ãŸã§0.0%衚èšã40代ã§ãããã0.1%ãšãªã£ãŠããŸãã
ã70代ãš80ä»£ã®æ»è
æ°ãå ããå²åã¯88%ã60代ãå ãããš96ïŒ
ãšãªããŸãã
ãã³ããã¯è¶çªãšå«ãã§ãã人ãã¡ããã³ããã¯å¯¿åœããšå«ã¶çç±ãäœãšãªãã§ãäŒãããŸãã§ããããã
ãæ¬¡ã«å ¥é¢ãã人ãšãéå·è ã®æ¯èŒã確èªããŸãã70代ã§98人ã§ãã

ãå
šãéçåããŠããŸããã30代ãŸã§éå·è
ã¯0人ã§0%ãäžçªå€§ãã70代ã§ãã98人ã®2.1%ã§ãããŸããéå·è
ãå
¥é¢ããäººã®æ°ã§å²ã£ãŠããŸãããéœæ§è
ã§å²ãã°ãïŒ
ã¯ãã£ãšäžããã§ãããã70代ã®éå·è
ã70代ã®éœæ§è
æ°ã§å²ãã°0.3%ã«ãªããŸãã
ãæ»äº¡æ°ã«å¯ŸããŠéçè
æ°ãããŸãã«å°ããã§ããïŒäŸãã°70ä»£ã®æ»äº¡æ°4,772人ã«å¯ŸããŠéçè
æ°98人ïŒãåŸã»ã©èå¯ããããŸãã
ã2021幎3æ3æ¥ãã2022幎4æ21æ¥ã§ããããŸã13ã«æåãçµéããŸããã
ã2022幎4æ21æ¥ã®æç¹ã§æ»è
æ°ã¯29,151人ã§ãã
ãã¯ã¯ãã³ãæã£ãŠããã®ã«ãæ»è
ãæžãã©ãããå¢ããŠããŸãã
ããªãã¯ãã³æ ªã¯ãããŸã§ã®æ°åã³ãããã匱æ¯åããŠããã®ã§ããæ»è
ãå¢ããŠããŸãã
ãæ¬¡ã«ååŽçïŒæ§å¥ã«ã¿ãæ»å é äœïŒç¬¬10äœãŸã§ïŒ2020幎12æããæ°åã³ããã®æ»äº¡çãèå¯ããŸãã
ã2020幎12æãŸã§ã®ã³ããæ»äº¡æ°ã¯3,466人ã§ã©ã³ãã³ã°å€ã§ãã2020幎ã¯äžæ
®ã®äºæ
ã38,133人ã§7äœãç·æ§éå®ã§ããèªæ®ºã13,588人ã§9äœã§ãã
ãçªç¶äºæ
ã«å·»ã蟌ãŸãã確çãããæ°åã³ããã§æ»äº¡ãã確çã¯äœãã§ãã
2-5ïŒæ°åã³ãããŠã€ã«ã¹ã®èå¯
ãæ°åã³ãããŠã€ã«ã¹ã®ååŽççµ±èšã ãã§ããæ»äº¡æ°ã»éå·è æ°ãšãã«å°ãªãäºãçè§£ã§ããããšæããŸãã
ãããããã¯æ»äº¡æ°ã«å¯ŸããŠéçè
æ°ãããŸãã«å°ããïŒäŸãã°70ä»£ã®æ»äº¡æ°4,772人ã«å¯ŸããŠéçè
æ°98人ïŒä»¶ã®èå¯ãããŠãããŸãã
ãããã€ãæ°èèšäºã®èŠåºãã玹ä»ããŸãã
ãæ±æŽçµæžïŒã³ããæ»äº¡æ£è
ã®4å²ãå
ã
å¯ãããïœ£ã®æ³¢çŽ
ãèªå£²æ°èïŒç¬¬ïŒæ³¢ã®ãã³ããæ»è
ããïŒå²ã®æ»å ãã³ãã以å€
ããã®ä»ã«ãæ»å ãã³ãã以å€ã«ãé¢ããããPCRéœæ§ãªãã³ããæ»ãšããŠçºè¡šãããŠããèšäºã5ã€ã»ã©ææ¡ããŠããŸããããå
šãŠæ¶ããŠããŸããã
ãæ¥æ¬åã®10代ã³ããæ»äº¡è ã®æ¬åœã®æ»å ã¯äº€éäºæ ã§ãã
æ¥ãã¬NEWS24 R3.9.28
â GINMI (@UGinmi) October 15, 2021
10ä»£ç·æ§ã³ããæ»ã®ãã¥ãŒã¹
ã©ãèããŠãæ¥æ¬èªãããããã
ã ããæããŠé ãããã pic.twitter.com/CXLUNtS1kZ
ããªãæ»å ãã³ãã以å€ãªã®ã«ãé¢ããããPCRéœæ§ãªãã³ããæ»ãšã«ãŠã³ãããŠããã®ã§ãããã
ãNHKïŒåŒçç æ°åã³ããæ»è
ïŒïŒäººå¢ãããæç²ããŸãã
ãåçåŽåçããåéœéåºçã«å¯Ÿããæ°åã³ãããŠã€ã«ã¹ãžã®ææããããããã®åŸæ»äº¡ãã人ã«ã€ããŠãæ»å ãåãããæ°åã³ãããŠã€ã«ã¹ã§æ»äº¡ããææè
ãšããŠãã¹ãŠå
¬è¡šããããé£çµ¡ããã£ãã
ãçã¯ããæ°åã³ãããŠã€ã«ã¹ã®èŽæ»çãæããã«ããããã«ããããªã©å¥ã®ç
æ°ãæ»å ãšãªã£ãŠãã人ã¯èšäžããŠããªãã£ãããšè©±ããŠããŸãã
ãèªå£²æ°èïŒéçãŒããªã®ã«ããªãããæ»è ïŒäººãã®çâŠåå ã¯ãååŽçã«ãŒã«ãããã¿ã€ãã«ã®éãã§ãã
ãååŽçïŒæ°åã³ãããŠã€ã«ã¹ææçæ£è
ã®æ¥å€åã³æ»äº¡æã®é£çµ¡ã«ã€ããŠãã§å ã
ãšééããŠããŸãã
ãåïŒ éœéåºççã®å
¬è¡šããæ»äº¡è
æ°ã¯ãã©ããã¹ããã
ãæ°åã³ãããŠã€ã«ã¹ææçã®éœæ§è
ã§ãã£ãŠãå
¥é¢äžãçé€äžã«äº¡ããªã£ ãæ¹ã«ã€ããŠã¯ãå³å¯ãªæ»å ãåããããæ»äº¡è
æ°ããšããŠå
šæ°ãå
¬è¡šãããããé¡ãããããŸãã
èå¯
ãããã¯ãããŸã§ç§å人ã®èå¯ã»æšè«ã§ã蚌æ ã¯ãããŸããã
ãéœæ§è
ã§ããã°æ»å ãåããã³ããæ»ã«ã«ãŠã³ããããŠããã®ã¯äºå®ã§ããäºæ
æ»ã§ãã£ãŠãéœæ§è
ãªãã³ããæ»ã«ã«ãŠã³ããããŠãããšèããŠããŸãã
ãæ°åã³ãããŠã€ã«ã¹ã®çµ±èšã§ã¯ã70代ãš80ä»£ã®æ»è
æ°ãå ããå²åã¯88%ã60代ãå ãããš96ïŒ
ã§ããã
ããã®ã»ãšãã©ããå¥ã®çŸæ£ã寿åœã§äº¡ããªã£ãŠãããšèããŠããŸããæ°åã³ãããŠã€ã«ã¹åäœã®è
åšã§ãªããå
ã
æã£ãŠããç
æ°ãšã®å䜵ã§ãããã
ããŸãã2021幎3æ3æ¥ã®è³æã§70ä»£ã®æ»äº¡æ°4,772人ã«å¯ŸããŠéçè
æ°98人ã§ãããæ»äº¡æ°4,772ã®å
ãæ¬åœã«ã³ããåäœã®è
åšã§äº¡ããªã£ãæ¹ã¯éçè
æ°ãšåãã100人çšåºŠã§ã¯ãªãããšèããŠããŸãã
äºå®ãŸãšã
ãã³ããæ»è
æ°ã¯2020幎12ææ«ã«3,466人ã2021幎3æ3æ¥ã«7,366人ã2022幎4æ21æ¥ã«29,151人ã§ããã2幎3ã«æã®çŽ¯èšæ»è
æ°ã¯ã幎éã®äžæ
®ã®äºæ
æ»æ°ããå°ãªãã§ãã
ãååŽçã®ééã«ãããéœæ§è
ã§ããã°æ»å ãåããã³ããæ»ã«ã«ãŠã³ããããŠããŸãã
ã2021幎3æ3æ¥ã®è³æã§70ä»£ã®æ»äº¡æ°4,772人ã«å¯ŸããŠéçè
æ°98人ã§ãã